Moderna (MRNA)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Key Insights
Share Price
$52.90Market Cap
$20.33 BillionTotal Outstanding Shares
384.40 Million SharesTotal Employees
5,600Dividend
No dividendIPO Date
December 7, 2018SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.modernatx.com
Historical Stock Splits
If you bought 1 share of MRNA before July 22, 2010, you'd have 0.0025000000000000005 shares today.
| Execution Date | Split Amount |
|---|---|
| August 3, 2017 | 1-for-10 |
| December 23, 2011 | 1-for-10 |
| July 22, 2010 | 1-for-4 |
Cash Flow Statement
July 1, 2023 to June 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $-3.24 Billion |
| Net Cash Flow From Financing Activities, Continuing | $-119.00 Million |
| Net Cash Flow From Financing Activities | $-119.00 Million |
| Net Cash Flow From Investing Activities, Continuing | $2.02 Billion |
| Net Cash Flow, Continuing | $-1.34 Billion |
| Net Cash Flow From Operating Activities, Continuing | $-3.24 Billion |
| Net Cash Flow | $-1.34 Billion |
| Net Cash Flow From Investing Activities | $2.02 Billion |
Income Statement
July 1, 2023 to June 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Operating Expenses | $6.30 Billion |
| Net Income/Loss Available To Common Stockholders, Basic | $-5.87 Billion |
| Other Operating Expenses | $1.45 Billion |
| Cost Of Revenue | $3.38 Billion |
| Diluted Average Shares | $1.15 Billion |
| Costs And Expenses | $9.69 Billion |
| Income/Loss From Continuing Operations After Tax | $-5.87 Billion |
| Benefits Costs and Expenses | $9.38 Billion |
| Net Income/Loss | $-5.87 Billion |
| Income/Loss Before Equity Method Investments | $-4.25 Billion |
| Research and Development | $4.85 Billion |
| Diluted Earnings Per Share | $15.37 |
| Income Tax Expense/Benefit | $1.53 Billion |
| Income/Loss From Continuing Operations Before Tax | $-4.33 Billion |
| Income/Loss From Equity Method Investments | $-87.00 Million |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $15.37 |
| Revenues | $5.05 Billion |
| Basic Average Shares | $1.15 Billion |
| Gross Profit | $1.67 Billion |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Operating Income/Loss | $-4.63 Billion |
| Net Income/Loss Attributable To Parent | $-5.87 Billion |
Balance Sheet
July 1, 2023 to June 30, 2024
| Metric | Value |
|---|---|
| Other Current Assets | $9.26 Billion |
| Current Assets | $9.66 Billion |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Liabilities And Equity | $15.68 Billion |
| Wages | $187.00 Million |
| Current Liabilities | $2.36 Billion |
| Equity Attributable To Parent | $11.71 Billion |
| Equity | $11.71 Billion |
| Inventory | $399.00 Million |
| Liabilities | $3.97 Billion |
| Other Current Liabilities | $1.90 Billion |
| Accounts Payable | $279.00 Million |
| Noncurrent Liabilities | $1.60 Billion |
| Noncurrent Assets | $6.02 Billion |
| Assets | $15.68 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ2024 Financhle. All Rights Reserved.